Radiation with concurrent late chemotherapy intensification (‘chemoboost’) for locally advanced head and neck cancer

Corry, June; Rischin, Danny; Smith, Jennifer; D’Costa, Ieta; Huges, Peter G.; Sexton, Maree; Sizeland, Andrew; Lyons, Bernard; Peters, Lester J.

doi:10.1016/s0167-8140(99)00182-6

Cited by 56 publications

(28 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1,2 In the 1990s several centers demonstrated low rates of neck failure in patients who had a clinical complete response after RT. [3][4][5][6] These findings sparked interest in using the response to treatment to determine the need for a planned neck dissection after RT. At the University of Florida, computed tomography (CT) performed 4 weeks after completing RT was used to assess the nodal response in patients with cervical metastases.…”

Section: Resultsmentioning

confidence: 99%

Lymph node‐positive head and neck cancer treated with definitive radiotherapy

Yeung

Liauw

Amdur

et al. 2008

Cancer

View full text Add to dashboard Cite

We investigated the prognostic impact of absolute lymphocyte count (ALC) following induction chemotherapy in newly diagnosed adult acute lymphoblastic leukemia (ALL). Patients with ALC ≥350 cells/μL at day 28 had a median overall survival (OS) of 47.4 months when compared with 17.6 months for those with an ALC <350 cells/μL (HR = 1.98, P = 0.007). Among patients who achieved a complete remission, median event‐free survival (EFS) for those with ALC ≥350 cells/μL on day 28 was 42.1 months when compared with 13.9 months in those with ALC <350 cells/μL (HR = 2.08, P = 0.006). In multivariable analysis, the ALC on day 28 (<350 cells/μL vs. ≥350 cells/μL, P ≤ .0004 for OS and EFS) along with WBC at diagnosis (≤6.0 or >30.0 K/μL vs. >6.0–30.0 K/μL, P ≤ 0.002 for OS and EFS) and cytogenetics (abnormal vs. normal, P = 0.002 for OS and P = 0.02 for EFS) were independent prognostic factors of both OS and EFS. Combining these three factors segregates patients in three well‐defined risk groups. These data suggest that ALC can be used in combination with other prognostic features to better predict outcome and that targeting the immune system to improve ALC may be a worthwhile strategy in ALL. Am. J.Hematol. © 2012 Wiley Periodicals, Inc.

show abstract

Section: Resultsmentioning

confidence: 99%

Lymph node‐positive head and neck cancer treated with definitive radiotherapy

Yeung

Liauw

Amdur

et al. 2008

Cancer

View full text Add to dashboard Cite

show abstract

“…Cell-mediated immunity is a form of adaptive immunity that is mediated by T lymphocytes. Both T helper cells (CD4) and cytotoxic or T suppressor cells (CD8) are required for complete elimination of tumor cells and maintenance of longterm immune protection (2)(3)(4)(5)(6)(7). CD8 cytotoxic T lymphocytes (CTLs) can recognize and kill tumor cells expressing peptides that are presented by major histocompatibility complex (MHC) class I molecules, whereas CD4 T helper cells are activated by recognition of peptides presented by MHC Class II molecules (8).…”

Section: Introductionmentioning

confidence: 99%

Effects of Zinc Sulfate Supplementation on Cell-Mediated Immune Response in Head and Neck Cancer Patients Treated with Radiation Therapy

Sangthawan

Phungrassami

Sinkitjarurnchai

2015

Nutrition and Cancer

View full text Add to dashboard Cite

Zinc deficiency is an important factor that impairs cellular immunity and contributes to low T lymphocyte counts in head and neck cancers. Persistent T lymphopenia is clinically relevant in terms of tumor persistence and/or recurrence. The primary objective was to evaluate the impact of zinc sulfate supplementation on the absolute numbers of circulating T lymphocytes and T lymphocyte subpopulations. The secondary objectives were to evaluate overall survival, progression-free survival, and the adverse events of zinc sulfate. Seventy-two head and neck cancer patients were enrolled in a randomized, double-blind, placebo-controlled trial. Zinc sulfate 50 mg in 10 cc and an identically appearing placebo were self-administered 3 times daily at meal times. Blood samples were obtained for complete blood count, total T lymphocytes and T lymphocyte subpopulations before radiation therapy as baselines, at the fifth week during radiation therapy, and at the first month after completion of radiation therapy. The baseline characteristics of patients, tumors, and treatments and the baseline lymphocyte parameters were not significantly different between the 2 groups. Zinc sulfate supplementation during head and neck radiation therapy showed no increase in absolute numbers of circulating T lymphocytes, T lymphocyte subpopulations, or survival with acceptable side effects.

show abstract

“…Radiotherapy (RT) is a major treatment modality for the management of head and neck malignancies; a primary therapy for many early stage malignancies, an adjuvant therapy following surgical resection, and curative as well as palliative therapy in conjunction with concurrent chemotherapy (CT) for late stage and unresectable head and neck malignancies [5,8,9,[15][16][17]19]. A meta-analysis of 120 randomized trials and approximately 25,000 patients showed that the concomitant cisplatinbased RT/CT provided the most benefit for locoregional control and survival, both in head and neck squamous cell carcinomas and nasopharyngeal carcinomas [4] On the other hand, concomitant RT/CT has a higher level of toxicity compared to RT alone [4].…”

Section: Introductionmentioning

confidence: 99%